PerkinElmer buys in vivo MI developer VisEn
PerkinElmer of Waltham Mass., has acquired VisEn Medical, an in vivo molecular imaging technology company, for an undisclosed sum.
PerkinElmer said the acquisition will broaden its cellular imaging business, by expanding its technologies and capabilities into preclinical research undertaken in academic institutes and pharmaceutical companies.
VisEn of Bedford, Mass., said its fluorescence molecular imaging systems and reagents are currently used in applications involving research into cancer, inflammation, cardiovascular, skeletal and pulmonary diseases. The company offers a fluorescence agent portfolio and fluorescence molecular tomographic imaging systems. Founded in 2000, VisEn's customers include academic imaging facilities and departments, biologists, radiologists, medical imaging facilities (combined with CT/MRI/ultrasound), pharmaceutical therapeutic research departments and contract research organizations.
PerkinElmer said the acquisition will broaden its cellular imaging business, by expanding its technologies and capabilities into preclinical research undertaken in academic institutes and pharmaceutical companies.
VisEn of Bedford, Mass., said its fluorescence molecular imaging systems and reagents are currently used in applications involving research into cancer, inflammation, cardiovascular, skeletal and pulmonary diseases. The company offers a fluorescence agent portfolio and fluorescence molecular tomographic imaging systems. Founded in 2000, VisEn's customers include academic imaging facilities and departments, biologists, radiologists, medical imaging facilities (combined with CT/MRI/ultrasound), pharmaceutical therapeutic research departments and contract research organizations.